A5080770542- Gastroesophageal reflux and treatments
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal motility and disorders
- Veterinary medicine and infectious diseases
- Gastric Cancer Management and Outcomes
- Pharmacy and Medical Practices
- Inflammatory mediators and NSAID effects
- Hernia repair and management
- Microbial Metabolites in Food Biotechnology
- Multiple Sclerosis Research Studies
- Biomedical Ethics and Regulation
- Chemical synthesis and pharmacological studies
- Myofascial pain diagnosis and treatment
- Drug Solubulity and Delivery Systems
- Respiratory and Cough-Related Research
- Vitamin D Research Studies
- Potassium and Related Disorders
- Hormonal Regulation and Hypertension
- Acute Lymphoblastic Leukemia research
- Bone health and osteoporosis research
- Bone Metabolism and Diseases
- Biliary and Gastrointestinal Fistulas
- Pharmacological Effects of Natural Compounds
- Polyomavirus and related diseases
- Abdominal vascular conditions and treatments
Sechenov University
2013-2024
Ministry of Health of the Russian Federation
2024
Helicobacter pylori infection can serve as one of indications to clarithromycin prescription. H. eradication is performed commonly a treatment for diseases caused by this pathogen and conditions with an increased risk complications (precancerous changes the gastric mucosa, unspecified iron deficiency anemia, idiopathic thrombocytopenic purpura, long-term NSAIDs use, anti-platelet drugs use etc). A number functional characteristics determines specific requirements schemes: high sensitivity...
A comparative dissolution kinetics test (CDKT) and bioequivalence studies of generic proton pump inhibitors (PPIs) do not model pharmacological acid suppression (PAS) pathological duodenogastric reflux (PDGR). This study aimed to them in CDKT assess drugs stability potential pantoprazole-clarithromycin interactions.In CDKT, PDGR (dissolution medium pH 7.00 ± 0.05, preexposure at 1.20 0.05) PAS (pH 4.00 were modelled for original pantoprazole (OP) its generics (GP1-4). In with...
The article tells about intermediate results of a comparative study the efficacy and tolerability Lavacol® in treatment chronic constipation. group consisted patients receiving Lavacol®, control included after with Forlax. Comparison findings obtained before within same periods from beginning treatment, showed no significant difference between groups. demonstrated high safety similar to that Forlax for symptomatic constipation functional constipation-predominant irritable bowel syndrome (in...
Among the defecating disorders with constipation or diarrhea, there is a group of major intestinal defined by Rome IV Diagnostic Criteria (2016): irritable bowel syndrome, functional constipation, diarrhea. The presence several updates criteria due to current lack objective signs listed while many options for describing subjective sensation patients from different countries. It calls their terminological multilingual standardization. Both and diarrhea can be caused variety exogenous...
Background Acute small bowel obstruction caused by bezoars is rare and, therefore, this problem not well known a community of doctors worldwide. Hence, there high frequency diagnostic and tactical errors often probability late operations. The aim research to study possible reasons for the bezoar formation, clinical course treatment intestinal bezoars.
Предложена и проверена гипотеза о том, что патологический дуоденогастральный рефлюкс медикаментозная кислотосупрессия могут снижать устойчивость препаратов омепразола с кишечнорастворимой оболочкой. С помощью модифицированного теста сравнительной кинетики растворения изучали кинетику оригинального (РП) 4 воспроизведенных (ВЛС1, ВЛС2, ВЛС3, ВЛС4) разных производителей в умеренно кислой среде, имитирующей среду желудка, при медикаментозной кислотосупрессии на модели патологического...
В обзоре литературы освещено современное состояние проблемы оценки безопасности одного из наиболее широко применяемых в клинической практике прокинетика и антиэметика — домперидона. Особое внимание уделено потенциальной кардиотоксичности препарата, механизмов ее развития факторов риска. Для снижения риска дозозависимых побочных эффектов препаратов созданы новые лекарственные формы, обеспечивающие поддержание концентрации действующего вещества плазме крови пределах терапевтического диапазона....
Background